BAY 1841788
Phase 2
BayerBAY 1841788 is one of 28 therapeutic programs targeting Diabetic Macular Edema. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
180 competitors in Diabetic Macular Edema
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Beovu
NovartisPhase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Synalar
EEurofarma Laboratorios S.A.
Phase 3
Lucentis
NovartisPhase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Intravitreal Ranibizumab
RochePhase 3
Glucophage
EMD SeronoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for BAY 1841788. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company